PDGFRB and idiopathic pulmonary fibrosis: The FDA-approved IPF drug Nintedanib is an inhibitor of multiple receptor tyrosine kinases including the platelet-derived growth factor receptor (PDGFR), the vascular endothelial growth factor receptor (VEGFR), and the fibroblast growth factor receptor (FGFR) [26, 27].